TurtleTree, a Singapore- and San Francisco-based maker of cell-based breast milk, has raised $30 million in the first tranche of its Series A funding led by European private equity firm VERSO Capital.
The new funds will go towards TurtleTree’s research, hiring, and developing functional ingredients found in human milk such as lactoferrin, the company, which opened a research office in Sacramento in September, said in a statement.
